Hyperlipidemia, Familial CombinedHyperlipidemiasTriglyceridesHypolipidemic AgentsLipidsCholesterolHypertriglyceridemiaCholesterol, LDLHyperlipoproteinemia Type IVLipoproteinsRisk FactorsApolipoproteins EHypercholesterolemiaLipid MetabolismApolipoproteins BCholesterol, HDLApolipoproteins CApolipoprotein E2Apolipoprotein C-IIILipoprotein LipaseFenofibrateXanthomatosisLipoproteins, VLDLAnticholesteremic AgentsSymptom AssessmentArteriosclerosisTreatment OutcomeDepressionHydroxymethylglutaryl-CoA Reductase InhibitorsLiverApolipoproteinsLipoproteins, LDLCholesterol, VLDLSeverity of Illness IndexGynostemmaObesityHyperlipoproteinemia Type IITime FactorsReceptors, LDLDietary FatsQuestionnairesPrevalenceHyperlipoproteinemia Type IIIAtherosclerosisPoloxamerProspective StudiesHeptanoic AcidsHypertensionDiabetes MellitusBlood GlucoseFollow-Up StudiesDiet, AtherogenicRetrospective StudiesMice, Inbred C57BLApolipoprotein A-IPostprandial PeriodCholesterol, DietaryDisease Models, AnimalBody WeightInsulin ResistanceCross-Sectional StudiesBehavioral SymptomsAge FactorsBezafibrateEpichlorohydrinFatty LiverDyslipidemiasDiabetes Mellitus, Type 2Psychiatric Status Rating ScalesSimvastatinComorbidityApolipoproteins AHyperlipoproteinemiasSex FactorsCardiovascular DiseasesPyrrolesInsulinPhytotherapyNephrotic SyndromeHyperlipoproteinemia Type VMice, KnockoutFatty Acids, NonesterifiedPhenotypeApolipoprotein E3GemfibrozilRegression AnalysisCohort StudiesGadiformesHyperglycemiaApolipoprotein B-48Lipoproteins, IDLPravastatinLongitudinal StudiesAffective SymptomsChylomicronsLipaseQuality of LifePlant ExtractsJapanDiet, High-Fat